Last updated: February 25, 2026
What is NDC 49348-0934?
NDC 49348-0934 refers to a proprietary formulation of ciprofloxacin, a fluoroquinolone antibiotic. It is used primarily for treating bacterial infections such as urinary tract infections, respiratory infections, and skin infections. The drug's formulation and packaging specifics can influence market competitiveness and pricing strategies.
Market Landscape
Patient Population
- Estimated global bacterial infection cases annually: 2 billion.
- U.S. outpatient antibiotic prescriptions: approximately 250 million per year (CDC, 2022).
- Ciprofloxacin captures roughly 25% of the fluoroquinolone market, translating to ~62 million prescriptions annually in the U.S.
Competitive Environment
- Established generics dominate the ciprofloxacin market.
- Leading brands: Cipro (Bayer), Ciloxin (Sun Pharma), and various generics.
- New formulations, including extended-release versions, are limited but emerging.
- Patent status: Ciprofloxacin's primary patents expired by 2006, leading to widespread generic availability.
Regulatory Factors
- FDA approval status indicates that NDC 49348-0934 is marketed under current conditions.
- No recent major regulatory actions affect ciprofloxacin, but warnings on tendonitis and neuropathy influence prescribing.
- Absence of exclusive rights limits pricing power but can position the product competitively through differentiation.
Price Analysis
Current Pricing Landscape
| Packaging Size |
Average Wholesale Price (AWP) |
Estimated Average Retail Price |
Market Share Implications |
| 250 mg tablets |
$0.25 per tablet |
$0.75 per tablet |
High due to extensive use |
| 500 mg tablets |
$0.50 per tablet |
$1.50 per tablet |
Dominant prescribing dose |
| 750 mg tablets |
Not commonly used |
N/A |
Less frequently prescribed |
Source: Red Book, 2022; National Average Drug Acquisition Cost (NADAC).
Price Trends
- Generic ciprofloxacin prices have declined significantly after patent expiry.
- The average retail price for a 250 mg tablet has declined by approximately 35% over the past five years.
- Market entry of biosimilar or unique formulations could slightly influence pricing.
Pricing Strategy for NDC 49348-0934
- Due to saturation in the generic market, pricing flexibility is limited.
- Market differentiation through improved bioavailability or dosing convenience can command premium pricing.
- Entry costs remain low, but market penetration depends heavily on formulary inclusion and physician prescribing habits.
Revenue Projection Model (2023-2028)
| Year |
Prescriptions (U.S.) |
Estimated Price per Unit |
Gross Revenue (U.S.) |
Comments |
| 2023 |
20 million |
$0.50 per tablet |
$10 million |
Entry phase, initial uptake |
| 2024 |
22 million |
$0.45 per tablet |
$9.9 million |
Price competition increases |
| 2025 |
24 million |
$0.40 per tablet |
$9.6 million |
Market stabilization |
| 2026 |
25 million |
$0.35 per tablet |
$8.75 million |
Market share stabilizes |
| 2027 |
26 million |
$0.30 per tablet |
$7.8 million |
Pricing pressures persist |
| 2028 |
27 million |
$0.30 per tablet |
$8.1 million |
Slight recovery through volume |
Assumptions: Steady prescription volume growth at 5% annually; no significant price hikes due to market saturation; competitive pressures limit pricing.
Key Influencing Factors
- Patent and exclusivity: Patent expiration has led to price erosion; no exclusivity for NDC 49348-0934.
- Generic competition: Dominates the market; significant price declines expected.
- Regulatory landscape: Safety concerns may influence prescribing, impacting demand.
- Market penetration: Requires targeted marketing and formulary access.
- Emerging resistance: Growing antibiotic resistance could decrease demand over time.
Conclusion
The ciprofloxacin market faces persistent price declines due to widespread generic competition. Innovative formulations or delivery mechanisms could enable premium pricing but face entry barriers. The market's saturation restricts pricing increases beyond small adjustments. Revenue projections suggest modest growth driven mainly by volume increases rather than price hikes.
Key Takeaways
- The ciprofloxacin market is highly saturated with generics, constraining pricing power.
- Demand remains stable, with potential growth driven by prescription volume rather than price.
- Market entry costs are low, but gaining share requires formulary access and clinician adoption.
- Prices have declined by approximately 35% over five years; further decreases are likely.
- Differentiation through formulation improvements offers the best chance for premium pricing.
FAQs
Q1: What is the main competitive threat to NDC 49348-0934?
Existing generic ciprofloxacin formulations dominate, with prices low and high prescription volumes.
Q2: How do regulatory warnings impact market share?
Warnings on tendonitis and neuropathy may reduce prescribing rates, especially among high-risk populations.
Q3: Can premium pricing be achieved?
Only if the formulation provides clear advantages over generics, such as improved efficacy or convenience.
Q4: What factors might reverse the declining price trend?
Introduction of novel formulations, shortages in supply, or regulatory restrictions could temporarily increase prices.
Q5: Is there potential for market growth?
Moderate growth is possible in specific niches or through successful formulary inclusion, but overall volume growth faces limits.
References
- Centers for Disease Control and Prevention. (2022). Antibiotic prescribing and use in the United States.
- Red Book. (2022). Pharmaceutical pricing data.
- FDA. (2022). Ciprofloxacin prescribing information and safety warnings.
- IMS Health. (2022). US outpatient prescription trends.
- Statista. (2022). Antibiotic market revenue projections.
